Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.

Journal of clinical medicine·2026
Same author

Report of the scientific network Holimitox on succinate dehydrogenase inhibitor (SDHI) pesticides: new insights and challenges with an EcoHealth approach-presentations and round tables from the Holimitox day on November 7, 2024.

Environmental science and pollution research international·2026
Same author

Shared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson's diseases.

NPJ Parkinson's disease·2026
Same author

Correction: Heart rate variability provides prognostic value in multiple system atrophy.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

Related Experiment Video

Updated: Jan 4, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.6K

Multiple System Atrophy: Recent Developments and Future Perspectives.

Wassilios G Meissner1,2,3,4, Pierre-Olivier Fernagut2,3,5,6, Benjamin Dehay2,3

  • 1CRMR Atrophie Multisystématisée, CHU Bordeaux, Service de Neurologie, Bordeaux, France.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 7, 2019
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a rare neurodegenerative disease. This review covers recent advances in understanding MSA pathogenesis, diagnosis, and treatment, highlighting the urgent need for neuroprotection.

Keywords:
MSAdiagnosisprognosistreatmentα-synuclein

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.9K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.9K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • Multiple system atrophy (MSA) is a rare, fatal neurodegenerative disorder.
  • Characterized by parkinsonism, cerebellar, and autonomic dysfunction.
  • Pathologic hallmark: aggregated alpha-synuclein in oligodendrocytes (glial cytoplasmic inclusions).

Purpose of the Study:

  • Critically appraise significant developments in MSA over the past decade.
  • Focus on pathogenesis, diagnosis, prognosis, and treatment development.
  • Discuss unsolved questions and future perspectives in MSA research.

Main Methods:

  • Literature review of recent advancements in Multiple System Atrophy (MSA).
  • Critical appraisal of studies focusing on pathogenesis, diagnosis, prognosis, and treatment.
  • Synthesis of current knowledge and identification of research gaps.

Main Results:

  • Significant progress in understanding MSA pathogenesis and diagnosis.
  • Limited advancements in neuroprotective treatments, highlighting an unmet need.
  • Established MSA as a synucleinopathy, alongside Parkinson's disease and Lewy body dementia.

Conclusions:

  • Despite recent progress, the pathogenesis of MSA remains incompletely understood.
  • Symptomatic treatments are available, but effective neuroprotection is still lacking.
  • Further research is crucial to address unsolved questions and develop effective therapies for MSA.